Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. David Jagielski (Eli Lilly): A top pharma stock that I wouldn't hesitate to buy right now and hold ...

One of them had to do with Citadel's position in the pharmaceutical giant Eli Lilly (NYSE: LLY). Ken Griffin and his team ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Back in December, I argued why I was ready to upgrade the stock of the embattled weight loss drugs leader Eli Lilly and Company ... Although I think dip-buying is expected to occur as investors ...

Eli Lilly has rebounded somewhat since ... It's also not possible to know whether the stock market's recent dip will last. Maybe it will turn into a full-blown bear market, or equities will ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

We recently published an article titled Jim Cramer Discusses These 10 Stocks & Says Bitcoin Created "Froth" In The Market. In this article, we are going to take a look at where Eli Lilly and Company ...

The S&P 500 (SNPINDEX: ^GSPC) is cooling off after rip-roaring gains of over 20% in both 2023 and 2024. The Nasdaq Composite ...

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...

The firm’s latest GLP-1 tracker is said to show Lilly’s market share rising to 49.1% for the four-week period ending February ...